Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
108-117 |
Var |
denotes |
Mutations |
T2 |
121-126 |
Gene |
denotes |
SHP-2 |
T3 |
127-138 |
Enzyme |
denotes |
phosphatase |
T4 |
150-165 |
PosReg |
denotes |
hyperactivation |
T5 |
173-191 |
MPA |
denotes |
catalytic activity |
T33 |
216-231 |
Disease |
denotes |
human leukemias |
T34 |
246-278 |
Disease |
denotes |
juvenile myelomonocytic leukemia |
T10 |
1314-1319 |
Gene |
denotes |
SHP-2 |
T11 |
1320-1333 |
Var |
denotes |
E76K mutation |
T12 |
1341-1375 |
Disease |
denotes |
myeloproliferative disease in mice |
T13 |
1494-1547 |
Var |
denotes |
E76K mutation in the N-terminal Src homology 2 domain |
T14 |
1548-1557 |
PosReg |
denotes |
increased |
T15 |
1558-1570 |
Interaction |
denotes |
interactions |
T18 |
1574-1580 |
Var |
denotes |
mutant |
T17 |
1581-1586 |
Gene |
denotes |
SHP-2 |
T16 |
1592-1596 |
Protein |
denotes |
Grb2 |
T19 |
1624-1639 |
PosReg |
denotes |
hyperactivation |
T20 |
1643-1709 |
Pathway |
denotes |
IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways |
T25 |
1748-1756 |
PosReg |
denotes |
increase |
T26 |
1764-1782 |
MPA |
denotes |
catalytic activity |
T24 |
1784-1810 |
MPA |
denotes |
dephosphorylation of STAT5 |
T22 |
1814-1819 |
Gene |
denotes |
SHP-2 |
T23 |
1820-1824 |
Var |
denotes |
E76K |
T21 |
1829-1837 |
NegReg |
denotes |
dampened |
T27 |
1852-1919 |
Var |
denotes |
catalytically inactive SHP-2 E76K with an additional C459S mutation |
T28 |
1947-1955 |
PosReg |
denotes |
increase |
T29 |
1960-1971 |
Interaction |
denotes |
interaction |
T30 |
1977-1981 |
Protein |
denotes |
Gab2 |
T31 |
1989-1996 |
PosReg |
denotes |
enhance |
T32 |
2001-2031 |
Pathway |
denotes |
activation of the PI3K pathway |
R1 |
T3 |
T2 |
ThemeOf |
phosphatase,SHP-2 |
R10 |
T17 |
T15 |
ThemeOf |
SHP-2,interactions |
R11 |
T18 |
T17 |
ThemeOf |
mutant,SHP-2 |
R12 |
T14 |
T19 |
CauseOf |
increased,hyperactivation |
R13 |
T20 |
T19 |
ThemeOf |
IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways,hyperactivation |
R14 |
T26 |
T25 |
ThemeOf |
catalytic activity,increase |
R15 |
T24 |
T21 |
ThemeOf |
dephosphorylation of STAT5,dampened |
R16 |
T23 |
T22 |
ThemeOf |
E76K,SHP-2 |
R17 |
T22 |
T24 |
ThemeOf |
SHP-2,dephosphorylation of STAT5 |
R18 |
T27 |
T28 |
CauseOf |
catalytically inactive SHP-2 E76K with an additional C459S mutation,increase |
R19 |
T29 |
T28 |
ThemeOf |
interaction,increase |
R2 |
T2 |
T1 |
ThemeOf |
SHP-2,Mutations |
R20 |
T30 |
T29 |
ThemeOf |
Gab2,interaction |
R21 |
T27 |
T31 |
CauseOf |
catalytically inactive SHP-2 E76K with an additional C459S mutation,enhance |
R22 |
T32 |
T31 |
ThemeOf |
activation of the PI3K pathway,enhance |
R3 |
T1 |
T4 |
CauseOf |
Mutations,hyperactivation |
R4 |
T5 |
T4 |
ThemeOf |
catalytic activity,hyperactivation |
R5 |
T10 |
T11 |
ThemeOf |
SHP-2,E76K mutation |
R6 |
T11 |
T12 |
CauseOf |
E76K mutation,myeloproliferative disease in mice |
R7 |
T13 |
T14 |
CauseOf |
E76K mutation in the N-terminal Src homology 2 domain,increased |
R8 |
T15 |
T14 |
ThemeOf |
interactions,increased |
R9 |
T16 |
T15 |
ThemeOf |
Grb2,interactions |